Search PubMed⌕ Search

Biomedical subjects

T L Petty

Publications and source records attributed to T L Petty.

At least 37 records · Page 2Linked to original sources

Five year survival and later outcome of patients with X-ray occult lung cancer detected by sputum cytology.

BACKGROUND: A cohort of 51 consecutive patients with roentgenographically occult lung cancer, identified by sputum cytology and confirmed by bronchoscopy was reported previously. METHODS: All patients have now been followed beyond 5 years and the causes of death ascertained. RESULTS: The actual 5-year survival of 27 patients who were resected for cure was 74% including death for all causes. The 5-year survival of all patients who received either surgery or radiation in an attempt to cure was 54.3%. Twelve secondary cancers were found by sputum cytology; eight of these patients have died. CONCLUSIONS: Sputum cytology can be useful in the identification of early stage lung cancer in patients at high-risk where the chances of cure are favorable.

Aged↗

Scope of the COPD problem in North America: early studies of prevalence and NHANES III data: basis for early identification and intervention.

COPD is a common disease that is often not diagnosed in the primary-care setting. This review highlights the findings of studies ranging from the early 1960s to the third National Health and Nutrition Examination Survey (NHANES III) study, undertaken to try and accurately estimate the prevalence of COPD in the US population. Results of the NHANES III indicate that COPD remains frequently underdiagnosed, and that spirometry should be more widely used in the primary-care setting to identify asymptomatic disease. Early intervention, in particular smoking cessation, could alter the course and outcome of disease in patients with COPD.

Health Surveys↗

Historical highlights of long-term oxygen therapy.

The story of the development of oxygen and its role in mitigating the ravages of chronic stable hypoxemia have been fascinating. Today, over one million Americans receive home oxygen each day, usually for COPD, from one of the three available systems. The future requires less expensive, highly portable, and practical devices for use during all activities of daily living.

Ambulatory Care↗

Ambulatory oxygen therapy, exercise, and survival with advanced chronic obstructive pulmonary disease (the Nocturnal Oxygen Therapy Trial revisited).

The NOTT study showed improved survival in COT patients who received LTOT for longer periods (mean 17.7 h/d, median 19.4 h/d) from an ambulatory oxygen system, compared with the survival of NOT patients who received oxygen for a mean of 11.8 h/d from a stationary system. The differences in survival could have been due to the method or the duration of oxygen therapy, or both. An increase in cardiac output and increased oxygenation of the arterial blood (oxygen content) results in increased tissue oxygen transport. In addition, COT was associated with better survival and reduced hospitalizations, compared with NOT patients who were unable to increase their walking level.

Ambulatory Care↗

Recommendations of the Fifth Oxygen Consensus Conference. Writing and Organizing Committees.

It should be recognized that the advent of LTOT created a new health care system that is based on powerful scientific data. Oxygen therapy studies such as those by the Nocturnal Oxygen Therapy Trial Group and the British Medical Research Council study clearly demonstrated that LTOT improves both the length and quality of life of hypoxemic COPD patients. Keeping patients at home and out of the hospital or nursing home has both psychosocial and economic benefits. Efforts should be towards enhancing, not limiting., the availability of LTOT.

Home Care Services↗

COPD. Interventions for smoking cessation and improved ventilatory function.

Chronic obstructive pulmonary disease (COPD) is a spectrum of smoking-related diseases that includes chronic bronchitis, emphysema, and asthmatic bronchitis. Smoking injures airways and alveoli, which invokes inflammatory processes in the respiratory tract that are mediated by oxidants, proteases, and inflammatory cytokines. Early identification of respiratory function loss and intervention are necessary to prevent progression to the disabling stages of COPD. Spirometry is a useful tool for assessing responses to smoking cessation and bronchoactive drugs. Anti-inflammatory drugs and antibiotics are useful to deal with exacerbations of bronchitis. Patient education and oxygen can improve the quality and duration of life in early and advanced stages of COPD.

Antidepressive Agents, Second-Generation↗

Testing patients' lungs: spirometry as part of the physical examination.

Spirometric measurements of lung function are vital signs that unfortunately are not as widely used as blood pressure or cholesterol testing. Spirometry is an uncomplicated procedure that can easily be incorporated by primary care physicians into routine physical examinations, especially now that simple handheld spirometers suitable for all offices are available. Abnormal spirometric patterns can alert physicians to patients' additional risk of developing chronic lung disease and to the need for interventions that prevent or forestall morbidity and mortality. Spirometry also is an important tool for monitoring patients' response to therapy in a number of disorders (eg, asthma). Spirometric testing in adults should begin at age 40 for smokers and patients with unexplained dyspnea, cough, wheezing, or excessive mucus. Children with asthma and cystic fibrosis should be identified and followed with spirometry.

Family Practice↗

Controversial indications for long-term respiratory care: long-term oxygen therapy.

Long-term oxygen therapy is the only therapy proven to alter the late course of chronic obstructive pulmonary disease, but it should be reserved for selected patients. Only patients with chronic, stable hypoxaemia and with associated organ system dysfunction should have long-term oxygen therapy prescribed. It is highly likely that the delivery of oxygen via ambulatory systems is superior to oxygen available solely from a stationary source. Transtracheal oxygen appears to be an advance in selected patients. Newer oxygen technologies will continue to provide improved methods of care for patients with advanced hypoxaemic states.

Humans↗

Screening and early intervention for COPD.

Chronic obstructive pulmonary disease is on the increase. Therapeutic improvement is limited by the irreversible nature of lung tissue loss. Basic lung function tests can detect early loss of function, which may facilitate smoking cessation and other interventions likely to delay disease progression. The advent of inexpensive portable spirometers promises to permit such testing in the primary care physician's office.

Adult↗

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma.

BACKGROUND: Airway inflammation is a hallmark of asthma, therefore current treatment recommendations include the use of inhaled glucocorticosteroids (GCS). However, there is little evidence that the effects of inhaled GCS are dose dependent. OBJECTIVES: The objective of this study was to assess the efficacy and safety of a second-generation GCS, budesonide, delivered by Turbuhaler, in adults with chronic asthma. METHODS: In a 12-week, randomized, double-blind, multicenter, parallel-group study, 473 subjects 18 to 70 years of age received either placebo or budesonide (200, 400, 800, or 1600 microg total daily dose) administered twice daily. Primary efficacy end points were mean change from baseline for FEV1 and morning peak expiratory flow. Safety was assessed by reported adverse events and by a cosyntropin-stimulation test. RESULTS: The mean baseline FEV1 was 63% to 66% of predicted normal value between groups. All doses of budesonide were more effective than placebo (p < 0.001). The mean changes in morning peak expiratory flow were 12, 22, 27, and 30 L/min in the 200, 400, 800, and 1600 microg budesonide total daily dose groups, respectively, and -27 L/min for the placebo group. A statistically significant dose-response effect for the mean change from baseline over the 12-week study was seen for both morning peak expiratory flow and FEV1. Budesonide-treated subjects also demonstrated significant reduction in asthma symptoms and bronchodilator use compared with placebo. There were no clinically significant differences in treatment-related adverse experiences among groups. CONCLUSIONS: Budesonide administered by Turbuhaler exhibited a dose response and was effective at low doses. It was well tolerated and significantly more effective than placebo.

Adolescent↗

Supportive therapy in COPD.

Supportive therapy in COPD includes long-term oxygen therapy (LTOT) and patient support groups as two cornerstones in a comprehensive program of care known as pulmonary rehabilitation. The rich history of LTOT dating to the early 1960s and bolstered by excellent controlled clinical trials of the 1970s, along with additional advances, provided an effective therapy which improved both the quality and length of life in patients with COPD. Many patients with oxygen gain insight into coping with advanced COPD through patient support groups. The need for more cosmetically pleasing oxygen delivery systems to the nose, and future directions in providing oxygen in the home, remain challenges.

Adaptation, Psychological↗